A phase i trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Brain Neoplasms
  • Chemoradiotherapy
  • Dacarbazine
  • Glioblastoma
  • Quinolones

abstract

  • Tipifarnib is well tolerated at 300 mg bid given discontinuously (21/28 days) in 4-week cycles, concurrently with standard chemo/radiotherapy. A Phase II study should evaluate the efficacy of tipifarnib with radiation and TMZ in patients with newly diagnosed glioblastoma and not receiving EIAED.

publication date

  • December 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3020272

Digital Object Identifier (DOI)

  • 10.1016/j.ijrobp.2010.07.1997

PubMed ID

  • 20934264

Additional Document Info

start page

  • 1422

end page

  • 7

volume

  • 81

number

  • 5